The new list contains 174 products which will have their maximum retail price reduced, as well as 16 products which will no longer receive separate pricing status and have been demoted to general pricing. The average price reduction is reported to be 19%. Of the items on the price reduction list, 111 are from overseas manufacturers; of those on the separate pricing cancelation list, 13 are from overseas manufacturers including Lilly, Pfizer (2), Johnson & Johnson, Merck KGaA (3), Apotex, GSK, Takeda, Astellas, AstraZeneca, and Novartis. In other pricing news, the Anhui Provincial Pricing Bureau announced that it will cap maximum drug retail markups at RMB 10 beginning December 10.
The NDRC has released a new list of national maximum drug retail prices slated to go into effect as of December 12